FDA Clears Modular Medical's Pivot Insulin Pump, Enabling Q2 Commercial Launch
MODD sits 55% above its 52-week low of $3.552.
Summary
Modular Medical has received FDA 510(k) clearance for its Pivot tubeless insulin patch pump, a critical regulatory milestone that enables commercial sale in the U.S. This approval is a significant de-risking event for the company, which previously disclosed a severe liquidity crisis and substantial doubt about its ability to continue as a going concern, following a recent reverse stock split. The company plans initial customer shipments by the end of Q2 2026, targeting the underserved 'almost-pumper' market with its innovative two-part removable design. This clearance provides a clear path to potential revenue generation, which is vital for the company's financial stability. Investors will now closely monitor the success of the commercial launch, product adoption rates, and progress on further software enhancements and European CE Mark approval.
At the time of this announcement, MODD was trading at $5.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8M. The 52-week trading range was $3.55 to $34.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Access Newswire.